GE Healthcare Announces Preliminary Phase 3 Results for Flutemetamol
GE Healthcare announced the preliminary results of two Phase 3 studies of its investigational PET amyloid imaging agent, [18F]flutemetamol, where both studies met their primary endpoints. One study, in terminally ill patients who agreed to undergo brain autopsy, showed strong concordance between flutemetamol PET images and Alzheimer’s disease-associated beta amyloid brain pathology. The other study, in young healthy volunteers under age 40, had results concordant with the known lack of brain amyloid in this population. Full results of these studies will be presented in the coming months. [18F]Flutemetamol is a GE Healthcare PET imaging agent in development for the detection of beta amyloid.
[18F]Flutemetamol is one component of a broad portfolio of diagnostic solutions that GE Healthcare is currently developing in the Alzheimer’s field. GE Healthcare is taking a comprehensive approach to understanding AD through its ongoing research to uncover the causes, risks and physical effects of the disease. For example, the company is partnering with pharma to identify a biosignature, or a biological indicator, which may help physicians diagnose Alzheimer’s disease prior to the onset of clinical symptoms.
GE Healthcare Launches New Version of Centricity EDI Services
GE Healthcare IT announced the availability of Centricity* EDI Services 5.4, a proven eligibility, claim, and remittance clearinghouse for hospitals and physician practices. This release, which seamlessly connects with GE’s revenue cycle management products (Centricity Business, Centricity Practice Solution, and Centricity Group Management), streamlines complex billing workflows by electronically connecting providers to virtually any payer. Today, more than 1,900 Centricity revenue cycle management customers depend on Centricity EDI Services to process more than 200 million claims per year valued at over $215 billion dollars.
GE Healthcare completes Acquisition of SeqWright, Inc., Expanding Capabilities in Fast Growing Molecular Diagnostic Segment
GE Healthcare, a unit of GE (NYSE: GE) announced that it has acquired SeqWright, Inc., a provider of nucleic acid sequencing and other genomic services. The acquisition adds complementary genomics capabilities to Clarient, a unit of GE Healthcare and a leader in the fast-growing molecular diagnostics sector. The deal also provides a platform for Clarient to expand its clinical diagnostic offerings to include next generation sequencing. Financial terms of the acquisition were not disclosed.
GE Unveils First Intelligent Motion Correction for High Heart Rate Cardiac CT
Announcing a leap forward in advanced cardiac imaging, GE Healthcare introduced the FDA 510(k)-pending Discovery CT750 HD FREEdom Edition† at the opening of this year’s American College of Cardiology (ACC) Annual Scientific Session & Expo in Chicago. Addressing the main challenges of cardiac imaging – coronary motion, high heart rates, calcium blooming, plaque composition and accurate myocardial perfusion – the FREEdom Edition is designed to provide a new level of cardiac CT performance and to help physicians best serve patients.